XBiotech Announces Presentation of Data from Phase 2 Study Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa
Data Presented at the 7th Conference of the European Hidradenitis Suppurativa Foundation (EHSF) Provide Results that Corroborate HiSCR findings with iHS4 Scoring as a Measure of Efficacy
AUSTIN, Texas, Jan. 26, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today additional data analysis of its Phase 2 study evaluating XBiotech's True Human(TM) antibody, MABp1, as a treatment for Hidradenitis Suppurativa (HS). The study achieved its primary endpoint, showing significant treatment benefit using the HiSCR endpoint, which is the method used in the development of the only therapy currently approved for the treatment of HS. However, other methods of evaluating disease severity and response to treatment have been proposed. The iHS4 scoring system has recently been proposed as a new measure of HS disease severity 1 but its usefulness as a clinical measure has not been extensively studied. Investigators used data from the Phase 2 study to evaluate the iHS4 scoring method to see how it correlates with the HiSCR findings.
These findings will be presented at the European Hidradenitis Suppurativa Foundation (EHSF) Conference occurring in Rotterdam Netherlands February 7-9th. The poster presentation titled, "Validation of the iHS4 Score as an Outcome Measure for Hidradenitis Suppurativa (HS): Application in Treatment with MABp1 Targeting Interleukin-1alpha" will be featured beginning at 10:00 am, on the 8th of February, 2018.
The data presented are thus a retrospective analysis using the iHS4 score for all 20 patients who were randomized to receive either placebo or MABp1 therapy in the Phase 2 double-blind study. At least 30% decrease of the iHS4 score from the baseline at week 12 was associated with 100% sensitivity for positive HiSCR score (the efficacy measure used in the phase 2 study). This change was found in one (10%) and in four (40%) patients allocated to placebo and MABp1, respectively (p= 0.046).
Theodora Kanni, M.D., Ph.D., Attikon University Hospital in Athens, Greece where the study was conducted, commented, "We find these results intriguing as we believe the consistent trend of the iHS4 and HiSCR scores for the Phase 2 data demonstrate its accuracy in measuring outcomes in HS patients. We look forward to future use of this scoring as an additional measure of efficacy in the clinic." Prof. Evangelos J. Giamarellos-Bourboulis, M.D., Ph.D., who was the Principal Investigator and Co-coordinator for the study, also added, "The decrease of the iHS4 score among patients treated with MABp1 is a further proof of its efficacy in HS."
Results of the Phase 2 study were recently published in the Journal of Investigative Dermatology, reporting that the study met its primary endpoint and demonstrated a significant improvement in HS patients treated with MABp1 compared to control after 12 weeks of therapy (Response rate of 60% vs 10%, respectively (p=0.035)). The 20 patient double-blind, placebo-controlled study was designed to evaluate the safety and efficacy of MABp1, the Company's True Human antibody targeting interleukin-1 alpha (IL-1alpha), in patients with HS not eligible for anti-TNF therapy. Patients were randomized 1:1 to receive either MABp1 or placebo every 2 weeks for 12 weeks. Patients in the study underwent primary assessment of efficacy using Hidradenitis Suppurativa Clinical Response (HiSCR) scores at 12 weeks, continued by a follow up phase to assess time to relapse after an additional 12 weeks without therapy. Efficacy measures included assessment of HiSCR scores, a validated method for evaluating efficacy in HS patients, as well as quality of life assessment and ultrasonographic evaluation.
About True Human(TM) Therapeutic Antibodies
Unlike previous generations of antibody therapies, XBiotech's True Human(TM) antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech's True Human antibodies have the potential to harness the body's natural immunity to fight disease with increased safety, efficacy and tolerability.
XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human(TM) proprietary technology. XBiotech currently is advancing a robust pipeline of antibody therapies to redefine the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech also is leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce new therapies urgently needed by patients worldwide. For more information, visit www.xbiotech.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
1 Zouboulis CC, et al. Br J Dermatol 2017; 177: 1401.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: XBiotech, Inc via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Paper in Scientific Reports Highlights Ability of 4D Pharma’s MRx0004 to Protect Against Airway Inflammation in Severe Asthma14.8.2018 08:00 | Pressemelding
Data suggest that MRx0004 is a promising next-generation therapeutic for management of asthma LEEDS, United Kingdom, Aug. 14, 2018 (GLOBE NEWSWIRE) -- 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of live biotherapeutics, today announces the publication of a paper demonstrating that MRx0004, a live biotherapeutic derived from the human gut microbiome, can protect against airway inflammation by reducing both neutrophilic and eosinophilic infiltration in a mouse model of severe asthma. The paper “Bifidobacterium breve MRx0004 protects against airway inflammation in a severe asthma model by suppressing both neutrophil and eosinophil lung infiltration” (Raftis et al.) is published in the Nature Publishing Group journal Scientific Reports . Asthma is a phenotypically heterogeneous disease. Between 5-10 % of asthma patients have a severe form of the disease which is refractory to steroid treatment and whose symptoms cannot be controlled despite the application o
Bombardier Continues African Market Penetration with Pre-Owned Q40013.8.2018 17:19 | Pressemelding
PassionAir becomes first Bombardier operator in Ghana with three Q400 aircraft MONTREAL, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Bombardier Commercial Aircraft announced today that the company successfully placed three pre-owned Q400 turboprops with PassionAir from the Republic of Ghana. The airline acquired the aircraft through a dry-lease with a third party. “Bombardier has sold about 3,500 new regional aircraft to date, and we continue to be very active on the used aircraft market.” said David Speirs, Vice President, Asset Management, Bombardier Commercial Aircraft. “Our recent momentum on the pre-owned aircraft market worldwide is a clear indication that our products are addressing a growing need for regional air transportation, especially in emerging markets.” “Our market penetration in Africa continues to intensify, and we are pleased to welcome Passion Air as the first commercial airline operating a Bombardier regional aircraft in the Republic of Ghana,” said Jean-Paul Boutibou, Vice
SEMAFO: Armed Incident in Est Region13.8.2018 17:09 | Pressemelding
MONTREAL, Aug. 13, 2018 (GLOBE NEWSWIRE) -- SEMAFO Inc. (TSX, OMX: SMF) regrets to report that an armed incident occurred between the town of Fada and the Boungou Mine site in the Est region of Burkina Faso. As a result, five gendarmes and one sub-contractor employee lost their lives. Operations at the Boungou Mine were not affected. As a precautionary measure, we will be increasing our security measures and continue to closely monitor the situation with our partners to protect the safety of SEMAFO employees and our operations. The Corporation would like to express its deepest sympathy to families of the victims. About SEMAFO SEMAFO is a Canadian-based mining company with gold production and exploration activities in West Africa. The Corporation operates the Mana Mine in Burkina Faso, which includes the high-grade satellite deposit of Siou, and is targeting commercial production at the Boungou Mine in the third quarter of 2018. SEMAFO is committed to evolve in a conscientious manner to
Checkpoint Therapeutics Announces Clinical Data on EGFR Inhibitor CK-101 Selected for Late-Breaking Oral Presentation at IASLC 19th World Conference on Lung Cancer13.8.2018 14:00 | Pressemelding
NEW YORK, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today announced that preliminary safety and efficacy data from a Phase 1/2 clinical trial of CK-101 (also known as RX518), a third-generation epidermal growth factor receptor (“EGFR”) tyrosine kinase inhibitor (“TKI”) being evaluated in advanced non-small cell lung cancer, has been selected for a late-breaking oral presentation at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer, to be held September 23-26, 2018, in Toronto. "We are thrilled to announce that preliminary data from the Phase 1/2 trial of our novel third-generation EGFR inhibitor has been selected for a late-breaking oral presentation at the World Conference on Lung Cancer. This marks the
Mash Group Plc reports interim unaudited financials, H1 2018 ended 30th June 201813.8.2018 08:00 | Pressemelding
Mash Group reports record H1/18 revenue, up 99% from H1/17. With H1/18 lending volumes surpassing full year 2017 and a strong EBIT of EUR 5.5 million achieved, Mash Group is extremely well positioned to continue executing on its growth plan, comments CEO Hickson . Mash continued to grow rapidly in all markets during the second quarter, achieving record lending volumes and maintaining strong momentum. Strategic Highlights Mash increases the size of its structured financing facility with funds managed by affiliates of Fortress Investment Group LLC (NYSE:FIG), from EUR 120 million to EUR 200 million. Mash was recognized as one of the Fintech50, Europe’s leading list of FinTech companies. AI Global Media, award CEO Hickson ‘Most Influential FinTech CEO of the year 2018’. Operational Highlights Mash continued to grow rapidly in all markets during the second quarter, achieving a record Q2 2018 in terms of lending volumes (+27%) and revenues (+36%) compared to Q1 2018. Registered merchants fo
ATPCO Awarded Patent for Cacheless Airline Ticket Pricing Model13.8.2018 06:00 | Pressemelding
Establishes Technology Foundational to Next-Gen Airline Revenue Management Tools DULLES, Va., Aug. 13, 2018 (GLOBE NEWSWIRE) -- ATPCO today announced that it has been awarded Patent #10,032,195 by the United States Patent and Trademark Office to cover new technology, developed by its data scientists and technical architects, that enables construction of airline ticket prices using graph database and “functional programming” techniques. This technology permits a unique approach to calculating airfare prices that was not previously available. Airline ticket prices are built using diverse individual data components: fares, flight schedules, taxes, and various legal and governance structures. An airline also sets business restrictions, known as rules, to determine under what circumstances a fare may be offered, such as requiring a Saturday-night stay or during pre-determined promotional sale dates. All these elements must be referenced and incorporated into the final price of an airline ti
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom